Our news
Company news
Show all-
-
AMG Announces Partnership with Forbion
-
Forbion appoints Silva Deželan, PhD as Head of Impact and ESG
-
Forbion raises €1.35 billion across two funds
-
Angelika Amon Young Scientist Award for Forbion Fellow Melanie de Almeida, PhD
-
Forbion appoints Dr. Peter Høngaard Andersen as Operating Partner and Dr. Matt Cooper as Venture Partner
-
Forbion announces first close of Forbion Growth Opportunities Fund II at €470 million
-
Forbion appoints both Dr Ton Logtenberg and Dr Michael Hayden as Venture Partners
Portfolio news
Show all-
Forbion co-leads oversubscribed $157M Series B Financing Round in Engrail Therapeutics
-
Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients
-
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
-
Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease
-
Forbion co-leads €26 million Seed Financing with launch of Orbis Medicines
-
Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections
-
NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
-
Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program
Events
Show allPublications
Show all-
Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment
-
Forbion Impact Report 2022
-
Forbion Policy for Responsible Investments 2023
-
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment
-
Forbion Policy for Responsible Investments 2022
-
Forbion Policy for Responsible Investments 2021
-
Sustained-Release Steroid Options For DME Therapy
-
Whale Watching - What a decade of change at Big Pharma taught us about corporate phenotypes
Media content
Show all-
Fierce Biotech - ‘The fundamentals are really strong’: Why investors are staying loyal to European biotech in 2023
-
EUVC #223 - Podcast with Forbion Partner Juliette Audet
-
Pharma deal making: a bright spot amid the gloom
-
Sifted - The 10 most active techbio investors in Europe
-
Precision Financing
-
Life changing treatments for rare disease – a beacon of hope
-
BIA Finance Report - Forbion named the most active non-UK investor
-
Forbion Portfolio Company Inversago named in Labiotech list of "The hottest private biotech companies in Canada"